)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Sareum Holdings (SAR) investor relations material
Sareum Holdings H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary25 Mar, 2025
Executive summary
Completed Phase 1 trial for SDC-1801, showing strong safety, pharmacokinetics, and biomarker effects for once-daily dosing in autoimmune diseases, especially psoriasis; no serious adverse events.
Regained control and increased economic interest in SRA737 to 63.5% after license return, enabling new development and licensing opportunities.
Strengthened patent portfolio for SDC-1801 in the US, China, and Japan, enhancing competitive position.
Cash position strengthened to over £4 million at period end, with an additional £1.07 million raised post-period.
Operating expenses and loss after tax significantly reduced year-over-year due to lower clinical trial costs.
Financial highlights
Cash at 31 December 2024 was £4.1 million, up from £1.5 million at 30 June 2024 and £0.4 million at 31 December 2023.
Loss after tax for the six months to 31 December 2024 was just over £1.2 million, improved from £1.8 million (or restated £1.7 million) loss for the same period in 2023.
Revenue for the six months ended 31 December 2024 was £22,000; operating expenses were £1.3 million, down from £2.5 million in the prior year.
Net assets increased to £4.3 million as of 31 December 2024, compared to £1.2 million at 31 December 2023.
Received approximately £1.3 million in investment and R&D tax credit post-period.
Outlook and guidance
SDC-1801 aims for Phase 2 readiness by year-end, with long-term toxicology studies scheduled to complete in Q4 2025.
SDC-1802 preclinical studies are being accelerated, with manufacturing underway and target cancer selection planned.
SRA737 program under review for further commercialization and development, with potential clinical trials and active licensing discussions.
Dual strategy for SDC-1801: preparing for Phase 2 trial while exploring licensing opportunities.
Continued rigorous capital allocation and readiness to respond to new opportunities in kinase inhibitor therapeutics.
What is the focus of SDC-1801 Phase 2 trials?
Explain the improved SRA737 economic terms.
When will SDC-1801 toxicology studies commence?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sareum Holdings earnings date
H2 202523 Oct, 2025
Next Sareum Holdings earnings date
H2 202523 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Sareum Holdings plc is a UK-based biotechnology company focused on the discovery and development of small molecule therapeutics targeting cancer and autoimmune diseases. The company specializes in kinase inhibition and advances its drug candidates through preclinical and early clinical development stages. Sareum’s lead programs target immune and inflammation pathways, and the company collaborates with partners to support further development and commercialization. Sareum Holdings plc is headquartered in Cambridge, United Kingdom, and its shares are listed on the AIM.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage